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Abstract
The contribution of exercise to hyperthermia mediated by MDMA is not known. We recently 
showed that inhibiting the dorsomedial hypothalamus (DMH) attenuated spontaneous locomotion 
and hyperthermia and prevented deaths in rats given MDMA in a warm environment. The goal of 
this study was to confirm that restoring locomotion through a treadmill would reverse these effects 
thereby confirming that locomotion mediated by the DMH contributes to MDMA-mediated 
hyperthermia. Rats were randomized to receive bilateral microinjections, into the region of the 
DMH, of muscimol (80 pmol/100nl) or artificial CSF followed by a systemic dose of either 
MDMA (7.5 mg/kg, i.v.) or saline. Immediately after the systemic injection, rats were placed on a 
motorized treadmill maintained at 32°C. Rats were exercised at a fixed speed (10 m/min) until 
their core temperature reached 41°C. Our results showed that a fixed exercise load abolished the 
decreases in temperature and mortality, seen previously with inhibition of the DMH in freely 
moving rats. Therefore, locomotion mediated by neurons in the DMH is critical to the 
development of hyperthermia from MDMA.
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1. Introduction
Deaths involving the drug 3,4-methylenedioxymethamphetamine (MDMA) often occur at 
dance parties where the ambient temperature may be elevated, and users commonly engage 
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in vigorous exercise. Previous research has shown that exercise increases the toxicity and 
hyperthermia of MDMA (1, 2) but despite this, locomotion and exercise have been 
discounted as major contributors to hyperthermia from MDMA. If locomotion is a major 
contributor to heat-related deaths from MDMA, then understanding how stimulants evoke 
locomotion and allow persons to exert themselves to the point of heat stroke is an important 
step in developing prevention strategies.
We have previously shown that inhibiting neurons in the region of the dorsomedial 
hypothalamus (DMH) attenuates spontaneous locomotion, hyperthermia, and prevents 
mortality in rats given MDMA in a warm environment (3). Interestingly, inhibiting neurons 
in the region of the DMH had no effect on increases in brown adipose tissue (iBAT) 
thermogenesis, or on decreases in cutaneous blood flow mediated by MDMA (3). This 
suggests that locomotion may by itself be a significant contributor to the development of 
hyperthermia from MDMA.
The DMH, however, is involved in numerous physiologic processes that might also 
contribute to hyperthermia from MDMA: shivering (4), stress-evoked increases in heart rate 
and adrenocorticotropic hormone (5), and behavioral thermoregulation (6). Although there is 
a correlation between decreases in locomotion and decreases in hyperthermia from MDMA, 
it is unknown if it is locomotion or another effect produced by neurons in the DMH that 
contributes to hyperthermia from MDMA.
The objective of this study was to confirm that locomotion mediated by the DMH is an 
important contributor to hyperthermia from MDMA given to rats in a warm environment. 
To do this we used treadmills to isolate and control the amount of locomotion produced by 
rats given MDMA. We hypothesized that decreases in MDMA-mediated hyperthermia and 
mortality seen previously with inhibition of the DMH, would be abolished when locomotion 
was restored using a treadmill in DMH-inhibited rats given MDMA in a warm environment.
2. Results
2.1 Temperature curves
Running at an ambient temperature of 32°C quickly increased the body temperature of rats 
(Fig.1A). Independent of their group, all the rats reached body temperatures of 41°C by 40 
minutes. Rats who injected with MDMA (aCSF/MDMA and muscimol/MDMA), however, 
reached critical temperatures 16 min faster (p<0.05) than rats given saline (aCSF-Saline and 
Muscimol/Saline groups). There were no differences within the Saline or MDMA groups. 
This is in contrast to our previous paper where we showed that inhibiting the DMH 
significantly decreased the temperature of MDMA-treated rats (3). Therefore equalizing the 
amount of locomotion between groups of rats treated with MDMA reverses the temperature 
effects seen with inhibiting the DMH.
2.2 Heat accumulation
MDMA, compared to saline, also increased the rate of heat accumulation (Fig.1B). There 
were no differences within groups given MDMA (aCSF/MDMA vs. Musc/MDMA) or 
within groups given Saline (aCSF/Sal vs Musc/Sal). Furthermore, this data shows that of the 
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individual contributions to heat accumulation in rats treated with MDMA locomotion 
accounts for ~50%. The other half is likely the combination of impaired heat dissipation 
(through vasoconstriction) and non-shivering thermogenesis (through iBAT).
3. Discussion
When viewed in light of our previous work, the findings of this study demonstrate that 
decreases in the MDMA-mediated hyperthermia seen after inhibition of neurons in the 
DMH are due to reductions in locomotion.
In two previous papers we showed that inhibiting neurons in the DMH decreased 
spontaneous locomotion and hyperthermia produced by MDMA (3, 7). It was not known, 
however, if decreases in locomotion were the cause of attenuated temperatures or merely 
associated with them. As we show in this paper, restoring locomotion in DMH-inhibited rats 
also restores hyperthermia thereby confirming locomotion as a significant contributor to 
MDMA-mediated hyperthermia. It is important to note that non-locomotor effects are also 
important contributors to hyperthermia mediated by MDMA. The differences (~0.1°C/min) 
in the rate of heat accumulation between rats given MDMA and saline (Fig. 1B) are likely 
from non-locomotor contributions to heat accumulation such as iBAT thermogenesis and 
cutaneous vasoconstriction (3, 8, 9). In our previous paper we demonstrated that inhibition 
of the DMH increased survival but did not change iBAT thermogenesis or cutaneous 
vasoconstriction (3). Therefore, while locomotor and non-locomotor components of heat 
accumulation from MDMA are approximately equal, inhibition of locomotion alone is 
sufficient to prevent hyperthermia and mortality from MDMA. Furthermore, MDMA users 
cannot control changes in non-shivering thermogenesis or cutaneous blood flow. They can 
however volitionally decrease or stop locomotion. While it seems intuitive that locomotion 
would contribute to heat production, our study is the first to conclusively show this with 
MDMA, and is contrary to what many authors have previously asserted (10-14).
The contribution of exercise to hyperthermia in users of MDMA is of particular clinical 
relevance, as many people use MDMA and stimulants to facilitate dancing in hot crowded 
environments (15). This may be why the majority of published cases of hyperthermia from 
MDMA continue to occur in persons at dance venues. An important question arising from 
this is why users of MDMA don’t stop exercising when their core temperature becomes 
elevated. Under normal conditions in rodents and humans, exhaustion develops when core 
temperatures reach a critical threshold (16). In humans this is ~40°C (17) while in rodents it 
is between 41-42°C (18). Exhaustion is thought to be a protective mechanism preventing 
heat stroke (16). Therefore drugs that prevent exhaustion may also increase the risk of 
developing drug-induced hyperthermia. It has been previously shown that drugs that 
increase central concentrations of dopamine and norepinephrine (NE), in both rats and 
humans, delay the development of exhaustion in a warm environment (19-21). Further 
research is needed to determine if MDMA, which also increases extracellular concentrations 
of dopamine and NE (22, 23), prevents exertional-related exhaustion and thereby increases 
the risk for developing heat stroke.
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The mechanism by which MDMA activates neurons in the DMH is not currently known, but 
may involve monoaminergic receptors. Studies where monoamine receptors antagonists 
have been systemically administered have shown that D1, alpha-1, 5HT-2A receptor 
antagonists block hyperthermia and locomotion produced by MDMA (24-27). Of these, 
alpha-1 and 5-HT-2A receptors within the DMH are strong candidates. Within the 
hypothalamus the DMH region has one of the highest concentrations of NE (28), and 
receives afferents from many brain stem NE groups, including the locus coeruleus (29). The 
DMH is also richly innervated by serotonergic fibers originating in the median raphe and 
midbrain dorsal raphe nucleus (30-32). In addition, the DMH contains 5-HT2A receptors 
(33, 34) and has high concentrations of both serotonin and NE transporters (35). We are 
currently working on studies addressing both of these possibilities.
An important implication of our research is that the main hypothalamic contribution to the 
development of hyperthermia from MDMA is locomotion. While MDMA is known to 
increase non-shivering thermogenesis through iBAT, and to decrease heat dissipation via 
cutaneous vasoconstriction—these effects are not mediated by the hypothalamus. Our data, 
and that of other labs, suggest that these effects are mediated at the level of the spinal cord 
or in the periphery (3, 36). Madden and Morrison (2006) have shown that serotonin 
receptors in the intermediolateral region of the spinal cord augment sympathetic responses 
evoked by local injections of the glutamate agonist n-methyl-d-aspartate (37). MDMA is 
known to increase the release of serotonin in various brain regions, and through its effects 
on serotonin 2A/2C receptors increase the release of glutamate (38); to date however, the 
effect of MDMA augmenting glutamate release has only been demonstrated in the 
hippocampus (38). Whether similar effects may be occurring within the spinal cord to 
facilitate iBAT thermogenesis and possibly cutaneous vasoconstriction requires further 
study. MDMA may also affect iBAT and cutaneous blood flow by increasing circulating 
concentrations of NE. MDMA causes significant increases in plasma concentrations of NE 
(39), which may cause alpha-1 mediated vasoconstriction. MDMA also causes increases in 
plasma free fatty acids, which in combination with NE may increase non-shivering 
thermogenesis in iBAT and skeletal muscle (40).
In conclusion, locomotion mediated by neurons in the DMH is an important contributor to 
the development of hyperthermia from MDMA. Determining the mechanisms by which 
MDMA activates neurons in the DMH may lead to a better understanding of how MDMA 
causes exertional heat stroke.
4. Experimental Procedures
4.1 Animals
Male adult Sprague-Dawley rats (weight 300 ± 20 g; Harlan, Indianapolis, IN) were used in 
this study. The Indiana University Animal Care and Use Committee approved all 
procedures. Experiments were performed using single-housed rats that were maintained in a 
12 h light/dark cycle and fed ad libitum. Experiments were conducted on fully conscious rats 
between 10:00 a.m. and 4:00 p.m. in a specially designed environmental chamber (3).
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4.2 Chemicals
MDMA was generously provided by the NIH. All injection volumes were 1 ml/kg body 
weight. Muscimol (Sigma-Aldrich, St. Louis, MO) was dissolved in aCSF and stored at 
−20°C until the time of the experiment.
4.3 Surgery preparation
Rats were anesthetized with 1.5-2% isoflurane in oxygen; heart rate and oxygen saturation 
were monitored during surgery using a Pulse Oximeter monitor (LS1P-10R, Nonin, 
Plymouth, MN). We first placed bilateral guide cannulas targeting the DMH, then we 
implanted a telemetric probe, and finally, we placed jugular venous catheters to allow for 
systemic drug administration. Rats were allowed to recover for at least 7 days after surgery 
before beginning treadmill experiments.
4.4 Guide cannula surgical implantation
Rats were placed in a stereotaxic apparatus with the incisor bar set at 3.3 mm below the 
interaural line. The skin overlying the dorsal surface of the skull was pretreated with 
lidocaine/epinephrine mixture, cut, and retracted followed by removal of soft tissue to 
expose the surface of the skull. The skull was treated with a 30% hydrogen peroxide 
solution using cotton-tipped applicators. This stopped bleeding, aided in sterility, and 
enhanced the visibility of sutures used as stereotaxic landmarks. Using a rotary tool 
(MiniMite Cordless 4.8V, Dremel, Racine, WI) equipped with a surgical carbide burr 
(DHP557, Miltex, Plainsboro, NJ), we made a small hole in the skull. We inserted the 
cannulas (26 gauge, Plastics One, Roanoke, VA) through the holes, and positioned them to 
target the DMH: AP −3.1 mm; LR ±2.0 mm; HD −8.2 mm using bregma as a reference 
point (Paxinos et al., 1998). We used a 10-degree angle from the sagittal plane to avoid 
central sinus and to allow bilateral placement of two cannulas. We placed two jeweler's 
screws (size 80) into the skull to facilitate attachment of the cement cap and secured the 
cannulae using Vetbond glue (3M, St. Paul, MN) and cranioplastic cement. Dummy-wire 
cannulas were then inserted into the guides until the day of the experiment.
4.5 Intravenous catheter implantation
Rats were placed in a sterile surgery field in a dorsal recumbent position exposing the neck 
and shoulder area. A small longitudinal incision was made rostral to the clavicle and the 
jugular vein was dissected and ligated. We inserted a catheter, constructed of 3.5 cm Silastic 
tubing (508-007, Dow Corning, Midland, MI) connected to 10 cm of Tygon tubing (Small 
Parts Inc., Miami FL,) with 1 cm of PE-50 tubing (Plastics One). The catheter was filled 
with saline and inserted Silastic end first, approximately 3 cm into the vein. We then routed 
the catheter subcutaneously, exteriorizing it at the dorsal neck area. The catheter was 
flushed, capped with a metal plug, and secured to the skin with sutures.
4.6 Temperature telemetric probe implantation
For the measurement of core body temperature, TA-F40 telemetric transmitters (DSI, St. 
Paul, MN) were placed intraperitoneally via a 2 cm-long longitudinal medial skin incision 
and muscular wall incision at the linea alba. Following insertion of the transmitter into the 
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abdominal cavity and surgical closure, rats were returned to their home cage for at least 1 
week before beginning treadmill familiarization.
4.7 Treadmill familiarization
Prior to experiments, rats were familiarized for at least 5 days to running on a motorized 
rodent treadmill (Columbus Instruments, Columbus, OH). Rats ran each day for 5 min at a 
zero incline and each day the speed was progressively increased to a maximum, by day 5, of 
18 m/min. Familiarization occurred at room temperature. Workloads of familiarization 
programs are not sufficient to induce training adaptations (41), but allow the rats to become 
accustomed treadmill running. A mild electric stimulus at the back of the treadmill chamber 
promoted the learning of running behavior.
4.8 Selection of speed for treadmill study
To find the appropriate speed for treadmill study in MDMA experiments we considered 
average locomotor responses to MDMA itself. In a Raturn® (BASi, LaFayette, IN) cage, the 
cage we used in our most recent study (3), rats are connected by a tether to a switch which 
activates the motor to rotate the bowl in the direction opposite to the movement of the 
animal. The time when the motor is activated can be recalculated to the number of rotations 
that the bowl makes to counteract the run of the animal. Considering the radius of the 
trajectory that the animal runs on average, we can estimate the speed of locomotion. In our 
experiments we have shown that peak locomotion between 25 and 30 min after injection of 
7.5 mg/kg MDMA measured in Raturn® cage was approximately 12.5 rotations per min (3). 
With the diameter of a circle run by the rat, which is defined by the diameter of the bowl at 
the level of bedding, being ~22 cm, we can estimate the speed as n*0.22*12.5=8.6 m/min. In 
another previously published study using telemetric transmitters (Data Sciences Inc.) in 
standard rat cages, the locomotion at 30 min after a dose of MDMA (7.5 mg/kg, i.p.) was 
approximately 20 units (14). As the manufacturer calibrates the system with 1 unit to equal 
~ 1 cm/sec, the average speed is equivalent to approximately 12 m/min (14). For the studies 
in this paper with MDMA we chose a treadmill speed of 10 m/min, which falls between our 
two previous studies (3, 14).
4.9 Effect of inhibition of neuronal activity in the DMH on body temperature during running 
with and without MDMA
The day before testing the rats were brought to experimental room and left overnight. To 
avoid the consequences of potential heat stroke, rats were tested only once. On the day of 
testing the cage with the rat was placed inside the environmental chamber and the animal 
was acclimated to the 32°C for ~60 min. Dummy-wire cannulas were then removed from 
guide cannulas, and microinjectors primed to deliver the appropriate injectate, were inserted 
into guide cannulas. Rats were randomized to one of four groups (n=5 per group). Rats 
received pretreatment with either bilateral microinjections into the DMH of aCSF or 
muscimol then half got either a slow systemic injection of saline or MDMA (7.5 mg/kg, 
i.v.). After acclimation, the microinjection pump was activated for 30 sec to deliver 100 nl 
of the aCSF or muscimol. Two min later the microinjectors were removed from the guide 
cannulas, and the flow was checked. Five min after the microinjection, rats received 
systemic injections of either MDMA or saline, and were immediately placed on the belt of 
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treadmill (Time 0) and the belt was advanced to 10 m/min. The rats were continuously 
monitored; when the body temperature reached 41°C the animal was immediately removed 
from the treadmill, and sacrificed by an overdose of Nembutal (100 mg/kg, i.p.). This was 
done to prevent undue suffering of the animal as we had previously noted that rats given 
MDMA in a warm environment have a high mortality rate when body temperature exceeds 
41°C (3).
4.10 Identification of injection sites
The rats were perfused transcardially with cold saline, followed by 4% paraformaldehyde. 
Brains were exteriorized, fixed overnight in 4% paraformaldehyde, then saturated in 23% 
sucrose in phosphate buffered saline, and frozen. Brain sections (40 µm) were prepared 
using a cryocut (Leica 1850). The microinjection sites were determined by an observer who 
was “blind” to the treatment group, in sections stained with Neutral Red using anatomical 
landmarks according to rat brain atlas (42). The confirmation of injection sites is shown in 
Figure 1C.
4.11 Data analysis and statistical procedures
Statistical analyses and graphing were performed using Prism (Graphpad Software, San 
Diego, CA) software. Analyses requiring between-group comparisons were performed using 
analysis of variance (ANOVA) with a least significant difference (LSD) post hoc test where 
indicated. Significance was defined as a p <0.05. Values are presented as means ± SEM.
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Highlights
• Decreases in MDMA-mediated hyperthermia caused by inhibiting neurons in 
the DMH are from reducing locomotion.
• Locomotion is largest contributor to heat accumulation from MDMA
• Neurons in the region of the DMH mediate locomotion from MDMA
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Figure 1. 
A: Inhibition of the DMH does not suppress hyperthermia induced by running on a treadmill 
in rats administered 80pmol/100nm muscimol plus either 7.5 mg/kg MDMA or saline. Solid 
lines represent rats treated systemically with MDMA (7.5 mg/kg) and dotted lines rats 
treated systemically with saline. Black lines represent rats microinjected with aCSF and grey 
lines microinjected with muscimol (80 pmol/100nl). The data represents time points for each 
respective group (either saline or MDMA) where no animal had reached a body temperature 
of 41°C.
B: The rates of heat accumulation in rats microinjected into the DMH with either muscimol 
(white columns) or aCSF (black columns) followed by the systemic administration of either 
saline (top columns) or MDMA (bottom columns). The rate was calculated as a slope of 
temperature increase during the linear portion of temperature increase between 6 and 14 min 
of running on the treadmill. * represents a difference (p<0.05) in the rates of heat 
accumulation between rats treated with MDMA and their corresponding saline control
C: A schematic of coronal brain section, adapted from the Paxinos and Watson (1998) atlas, 
with locations of injection sites. DMH=dorsal medial hypothalamus, VMH= ventromedial 
hypothalamus Microinjections of muscimol are denoted by filled circles and microinjections 
of aCSF by open circles.
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